ArticleCureus2026
Sustained Regression of Parotid Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma After Nutritional and Nutraceutical Intervention Without Chemoimmunotherapy: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) in the setting of Sjögren's syndrome (SS) is a well-recognized complication of chronic autoimmune salivary gland inflammation. Standard management options include radiotherapy, immunotherapy, and combination chemoimmunotherapy, with active surveillance reserved for stable, low-burden disease. The potential role of structured nutritional and nutraceutical intervention in this setting has not been previously described. We report the case of a woman who presented at age 52 with SS-associated bilateral parotid MALT lymphoma that progressed substantially over 28 months of active observation, with palpable bilateral parotid enlargement reaching 10 x 5 cm on the left and 6 x 6 cm on the right. Proposed chemoimmunotherapy was deferred by the patient, and she independently initiated a structured multicomponent protocol comprising a strict vegan diet restricted in methionine and cysteine, urinary alkalization, and orally administered nutraceuticals including therapeutic-dose slow-releasing sodium selenite (32 mg/day), B6 pyridoxal-5'-phosphate (P5P), iron, zinc, copper, and manganese, with adjunctive rectal ozone therapy started at approximately Month 3. Serial clinical examinations and ultrasonography documented progressive bilateral parotid regression from approximately Month 7. At Month 20, repeat ultrasonography confirmed substantial radiographic reduction: the right parotid lesion decreased to 1.5 × 0.8 cm and the left to 2.7 × 0.8 cm, with both parotid glands returning to normal overall size with residual hypoechoic lesions and no cervical lymphadenopathy. At approximately Month 19, the hematologist documented no significant lymphadenopathy or splenomegaly on serial physical examination. Prednisone dosing, prescribed for concurrent autoimmune hemolytic anemia (AIHA), fluctuated independently of parotid gland changes throughout, making a corticosteroid-mediated response unlikely. This case documents a rapid and durable regression of progressive bilateral parotid MALT lymphoma after a dietary and nutraceutical protocol targeting tumor redox biology, without chemoimmunotherapy. Although spontaneous regression cannot be excluded, the response timing and proposed mechanism of glutathione and thioredoxin antioxidant pathway disruption merit further clinical study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.